Clinical trial
Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel (+/- Trastuzumab) Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer
NCT00574587 is registered in ClinicalTrials.gov with Albert Einstein College of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel (+/- Trastuzumab) Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer
- Lead sponsor
- Albert Einstein College of Medicine
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- May 31, 2014
- Enrollment
- 55 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer